SLC5A2 and bone fracture: SGLT2 inhibitors did not significantly increase the risk of volume depletion [RR: 1.11 (0.98–1.25); P = 0.11; I2 = 0%], hypotension [RR: 1.05 (0.84–1.32); P = 0.65; I2 = 0%], hyperkalaemia [RR: 0.79 (0.49–1.29); P = 0.35; I2 = 0%], major hypoglycaemia [RR: 1.09 (0.84–1.42); P = 0.53; I2 = 9%], bone fractures [RR: 1.11 (0.89–1.39); P = 0.36; I2 = 0%], and urinary tract infections [RR: 1.08 (0.87–1.35); P = 0.48; I2 = 0%].